Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report

Large-cell neuroendocrine lung carcinoma (LCNEC) is a high-grade neoplasm with median survival of 1 year and limited therapeutic options. Here, we report the unusual case of a 47-yr-old female smoker with stage IV LCNEC featuring EML4–ALK variant 2 (E20:A20), wild-type TP53/RB1, and low tumor mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiedemann, Christiane, Kazdal, Daniel, Cvetkovic, Jelena, Kunz, Julia, Fisch, David, Kirchner, Martina, Kriegsmann, Mark, Sültmann, Holger, Heussel, Claus-Peter, Bischoff, Helge, Thomas, Michael, Stenzinger, Albrecht, Christopoulos, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2022
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632356/
https://www.ncbi.nlm.nih.gov/pubmed/36207130
http://dx.doi.org/10.1101/mcs.a006234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632356/
https://www.ncbi.nlm.nih.gov/pubmed/36207130
http://dx.doi.org/10.1101/mcs.a006234

Ejemplares similares